Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Mayo Clin Proc. 2024 Apr;99(4):542-550. doi: 10.1016/j.mayocp.2023.12.018.
To assess the use of cannabis as a symptom management strategy for patients with fibromyalgia.
An electronic, cross-sectional survey was conducted among patients diagnosed with fibromyalgia and treated in Integrative Medicine & Health at Mayo Clinic, Rochester, Minnesota. The survey was constructed with the Symptom Management Theory tool and was sent anonymously via web-based software to patients with a diagnosis of fibromyalgia.
Of 5234 patients with fibromyalgia sent the online survey, 1336 (25.5%) responded and met the inclusion criteria. Survey respondents had a median age of 48 (Q1-Q3: 37.5-58.0) years, and most identified as female. Nearly half of respondents (49.5%, n=661) reported cannabis use since their fibromyalgia diagnosis. The most common symptoms for which respondents reported using cannabis were pain (98.9%, n=654); fatigue (96.2%; n=636); stress, anxiety, or depression (93.9%; n=621); and insomnia (93.6%; n=619). Improvement in pain symptoms with cannabis use was reported by 82.0% (n=536). Most cannabis-using respondents reported that cannabis also improved symptoms of stress, anxiety, and depression and of insomnia.
Considering that cannabis is a popular choice among patients for managing fibromyalgia symptoms, clinicians should have adequate knowledge of cannabis when discussing therapeutic options for fibromyalgia with their patients.
评估大麻作为纤维肌痛患者症状管理策略的应用。
在明尼苏达州罗切斯特市梅奥诊所综合医学与健康中心接受纤维肌痛诊断和治疗的患者中进行了一项电子横断面调查。该调查是使用症状管理理论工具构建的,并通过基于网络的软件匿名发送给纤维肌痛患者。
在 5234 名患有纤维肌痛的患者中,有 1336 名(25.5%)回复并符合纳入标准。调查对象的中位年龄为 48 岁(四分位距 37.5-58.0),大多数为女性。近一半的受访者(49.5%,n=661)报告在诊断出纤维肌痛后使用过大麻。受访者报告使用大麻治疗的最常见症状是疼痛(98.9%,n=654);疲劳(96.2%,n=636);压力、焦虑或抑郁(93.9%,n=621);和失眠(93.6%,n=619)。报告使用大麻改善疼痛症状的受访者比例为 82.0%(n=536)。大多数使用大麻的受访者报告称,大麻也改善了压力、焦虑和抑郁以及失眠的症状。
鉴于大麻是患者管理纤维肌痛症状的热门选择,临床医生在与患者讨论纤维肌痛的治疗选择时,应该对大麻有足够的了解。